Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitamin O ? FDA says no

This article was originally published in The Tan Sheet

Executive Summary

R-Garden, marketer of dietary supplement Vitamin O, has been issued a warning letter regarding numerous violations of the FD&C Act, FDA says. Advertising claims made in mailings, customer testimonials and product descriptions found on the firm's website and in literature classify the supplement as a drug, and therefore would require an NDA, the agency states in the Feb. 8 letter. Questionable claims include testimonials that the oxygen-infused salt water, which can be topically applied or internally ingested, "took a skin cancer off my nose," "help[ed] control angina" and "stops gum infection and pain." R-Garden lacks sufficient scientific evidence to back its claims, the agency says, adding the product does not bear adequate dosing instructions, listed ingredients or recommended daily intakes...

You may also be interested in...

QUOTED. 19 February 2020. Stephen Hahn.

The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts